close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Celldex Therapeutics, Inc.

< Previous 1 2 Next >
News headline image
Celldex Reports First Quarter 2025 Financial Results and Provides Corporate Update
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Tickers CLDX
News headline image
Celldex Presents Histology Data from Phase 2 Study of Barzolvolimab in EoE Supporting Potential of Mast Depleting Agent in this Difficult to Treat Disease
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Tickers CLDX
News headline image
Celldex Therapeutics to Present at Upcoming Investor Conferences
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Tickers CLDX
News headline image
Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Tickers CLDX
News headline image
Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Tickers CLDX
News headline image
Celldex Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Tickers CLDX
News headline image
Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Tickers CLDX
News headline image
Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Tickers CLDX
News headline image
Celldex Therapeutics to Present at Upcoming Investor Conferences
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Tickers CLDX
News headline image
Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Tickers CLDX
News headline image
Celldex Announces Upcoming Late Breaking Oral Presentation of 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria at ACAAI 2024
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Tickers CLDX
News headline image
Celldex Therapeutics Presents Landmark 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV 2024
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Tickers CLDX
News headline image
Celldex Announces Upcoming Late Breaking Oral Presentation of 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV Congress 2024
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Tickers CLDX
News headline image
Celldex Therapeutics to Present at Upcoming Investor Conferences
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Tickers CLDX
News headline image
Celldex Reports Second Quarter 2024 Financial Results and Provides Corporate Update
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Tickers CLDX
News headline image
Celldex Therapeutics Presents Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Tickers CLDX
News headline image
Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Tickers CLDX
News headline image
Celldex Therapeutics to Present at Jefferies Healthcare Conference
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Tickers CLDX
News headline image
Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Tickers CLDX
News headline image
Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Tickers CLDX
News headline image
Celldex Reports First Quarter 2024 Financial Results and Provides Corporate Update
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Tickers CLDX
News headline image
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Tickers CLDX
News headline image
Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Tickers CLDX
News headline image
Celldex Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Tickers CLDX
News headline image
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Tickers CLDX
News headline image
Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Tickers CLDX
News headline image
Celldex Therapeutics Announces Proposed Public Offering of Common Stock
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Tickers CLDX
News headline image
Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Tickers CLDX
News headline image
Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Tickers CLDX
News headline image
Celldex to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Tickers CLDX
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today